Depo-Provera Lawsuit 2026: Brain Tumor Claims, Settlement Updates & Who Qualifies

What Is the Depo-Provera Lawsuit About?

The Depo-Provera lawsuit centers on claims that Pfizer — the manufacturer of the injectable contraceptive medroxyprogesterone acetate — failed to adequately warn users about a significantly elevated risk of developing intracranial meningioma, a type of brain tumor that forms on the membranes surrounding the brain and spinal cord.

Depo-Provera is a progestin-based contraceptive injection administered every three months. It has been used by millions of women worldwide since its FDA approval in 1992. While generally effective at preventing pregnancy, growing pharmacovigilance data — including a landmark 2024 study by France’s Agence Nationale de Sécurité du Médicament (ANSM) — found that long-term use dramatically increases the risk of meningioma formation.

The central legal allegation is that Pfizer knew or should have known about this risk based on emerging progestin research, yet failed to update its warning labels or inform prescribing physicians and patients. Plaintiffs argue this constitutes a failure-to-warn, negligence, and strict products liability.

The Science: How Depo-Provera Is Linked to Brain Tumors

The biological mechanism connecting medroxyprogesterone acetate to meningioma growth is well-established in medical literature. Meningioma cells express progesterone receptors, and exogenous progestins — especially at the sustained, high-dose levels delivered by Depo-Provera injections — are believed to stimulate tumor proliferation.

Key Research Findings

The pivotal 2024 ANSM pharmacovigilance study, published in the British Medical Journal, analyzed over 18,000 cases and found the following adjusted relative risk of intracranial meningioma by duration of Depo-Provera use:

• Less than 1 year of use: ~1.5x increased risk over baseline
• 1–3 years of use: ~2.2x increased risk
• 3–5 years of use: ~4.8x increased risk
• 5+ years of continuous use: ~5.6x increased risk
• High-dose, long-term use: up to 6.9x increased risk

Earlier studies from 2012 onward, including research published in the Journal of Neuro-Oncology and data from the WHO’s International Agency for Research on Cancer, had already identified progestins as a contributing factor in meningioma growth — raising questions about why Pfizer’s label updates lagged behind the science.

FDA Regulatory Response

In May 2023, the U.S. Food and Drug Administration (FDA) updated its safety communications to add meningioma to the list of potential risks associated with Depo-Provera use. However, plaintiffs argue this warning came years too late for women who had already developed tumors.

Who Qualifies to File a Depo-Provera Lawsuit?

You may be eligible to file a Depo-Provera brain tumor lawsuit if you meet the following general criteria. Eligibility varies by individual case and is subject to legal review, but the core requirements are:

Primary Eligibility Criteria

• Used Depo-Provera for at least 12 months continuously or cumulatively
• Received a diagnosis of intracranial meningioma — confirmed by MRI or pathology report
• Your meningioma diagnosis occurred after a documented period of Depo-Provera use
• Your diagnosis was made on or after January 1, 2010 (to fall within most applicable statutes of limitations)

Who May Have a Stronger Claim

• Women who used Depo-Provera for 3 or more years
• Those who required surgery, radiation, or experienced significant disability as a result
• Cases involving recurrent or malignant meningioma
• Wrongful death cases where a family member died as a result of a Depo-Provera-linked tumor

Statute of Limitations

Most states allow 2 to 3 years from the date of discovery — meaning from when you knew or reasonably should have known your meningioma may have been linked to Depo-Provera — to file a lawsuit. Given the 2023 FDA warning and the surge of media coverage in 2024, the clock may already be running. Contacting an attorney promptly is strongly advised.

Current Status of the Depo-Provera MDL (2026 Update)

In February 2024, the U.S. Judicial Panel on Multidistrict Litigation (JPML) centralized all federal Depo-Provera lawsuits into a single MDL proceeding: In re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3081, before Judge Matthew Kennelly in the Northern District of Illinois.

MDL Litigation Timeline

• February 2024: MDL centralized in N.D. Illinois; over 12,000 cases initially transferred
• Mid-2024: Case Management Orders entered; discovery phase opened; bellwether trial pool selected
• Late 2024 – Early 2025: Expert witness depositions; Daubert motions on causation filed
• 2025: Bellwether trial scheduling; early settlement mediation discussions between Pfizer and plaintiffs’ steering committee
• 2026 (Projected): First bellwether trials or global settlement resolution anticipated

As of May 2026, the MDL docket contains over 18,000 active cases. Legal analysts anticipate that the sheer volume of scientifically credible claims — backed by the 2024 ANSM study — makes a global settlement increasingly likely, potentially valued between $1 billion and $3 billion in total.

Depo-Provera Settlement Amounts: What Can You Expect?

No official Depo-Provera settlement has been announced as of this writing. You can compare these projected ranges with the Depo-Provera settlement calculator and our detailed Depo-Provera settlement amounts guide. However, based on comparable drug injury MDL settlements — including the Risperdal, Paragard IUD, and Essure litigation — legal experts project the following estimated compensation tiers:

Projected Settlement Ranges by Injury Severity

• Tier 1 — Minor or Benign Meningioma (Watch and Wait): $75,000 – $150,000
• Tier 2 — Moderate Injury Requiring Surgery: $150,000 – $300,000
• Tier 3 — Severe Injury with Disability or Neurological Damage: $300,000 – $600,000
• Tier 4 — Catastrophic Injury or Wrongful Death: $500,000 – $1,500,000+

Factors that influence individual settlement value include the duration of Depo-Provera use, severity of the tumor and resulting medical treatment, lost wages and earning capacity, pain and suffering, and whether there is evidence of Pfizer’s awareness of the risk.

Evidence You Will Need to Support Your Claim

A strong Depo-Provera lawsuit requires documenting the link between your use of the drug and your diagnosis. Your attorney will typically gather the following:

• Pharmacy records and prescription history confirming Depo-Provera injections and duration of use
• Medical records including MRI imaging showing the meningioma diagnosis, size, and location
• Surgical reports and pathology results if a procedure was performed
• Treating physician statements about the impact of the tumor on your health and functioning
• Employment records if lost income is part of your damages claim
• Prior medical history ruling out other known meningioma risk factors (prior radiation, NF2 gene mutation)

How to File a Depo-Provera Lawsuit in 2026

The process for joining the Depo-Provera MDL typically involves the following steps. For payout-focused guidance, see the Depo-Provera lawsuit payout guide.

1. Free case evaluation: Contact a mass tort attorney for a no-cost review of your eligibility. Most firms handling Depo-Provera cases work on a contingency fee basis — meaning no upfront costs to you.
2. Document gathering: Your attorney will help you request pharmacy records, medical records, and imaging studies to build your case file.
3. Complaint filing: Your attorney files a Short Form Complaint in the N.D. Illinois MDL, linking your case to the master complaint.
4. Discovery participation: You may be asked to complete plaintiff fact sheets and provide a deposition, as required by MDL discovery orders.
5. Settlement or trial: Most MDL cases resolve through negotiated global settlements before reaching individual trials.

Frequently Asked Questions About Depo-Provera Lawsuits

Can I still file a lawsuit if I stopped using Depo-Provera years ago?

Yes. As long as your meningioma diagnosis falls within the applicable statute of limitations — typically 2–3 years from the date you discovered the connection — you may still have a valid claim. The 2023 FDA warning and 2024 ANSM study may have reset the “discovery clock” for many women.

What if my meningioma was benign or didn’t require surgery?

You may still qualify. Even benign meningiomas can cause significant harm — including chronic headaches, vision problems, cognitive disruption, and anxiety. Surveillance requirements alone can impose substantial emotional and financial burdens that are compensable under tort law.

Does it matter which brand of medroxyprogesterone acetate I used?

The lawsuits currently focus on Depo-Provera (Pfizer’s brand-name injectable), but generic medroxyprogesterone acetate injections (such as Depo-SubQ Provera 104) may also be covered depending on your jurisdiction and the manufacturer involved. Your attorney can advise on this.

How long will the case take?

MDL litigation typically takes 2–5 years to reach resolution. However, early bellwether trial results in 2026 could accelerate settlement timelines significantly if plaintiffs’ verdicts are strong.

Is there a class action lawsuit for Depo-Provera?

No. The litigation is structured as a multidistrict litigation (MDL), not a class action. This means each plaintiff retains their own individual claim and receives individual compensation — not a pro-rata share of a fixed pool. MDL structure typically results in higher individual recoveries than class actions for personal injury cases.

Why Choose a Mass Tort Attorney for Your Depo-Provera Claim?

Depo-Provera litigation involves complex pharmaceutical science, federal MDL procedure, and negotiation with one of the world’s largest drug companies. Choosing an attorney experienced in mass tort drug litigation — particularly those already active in MDL No. 3081 — gives you the best chance at a favorable outcome.

Firms handling these cases work on a contingency fee basis: you pay nothing unless you recover compensation. Most evaluations are free and confidential.